Agenus gains rights to Selexis SUREtechnology platform

Switzerland-based biotech Selexis has signed additional commercial license agreements (CLAs) with Agenus (Nasdaq: AGEN), a US immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies.

Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins. Financial terms of the deal were not disclosed.

“It’s gratifying to have the opportunity to play a part in Agenus’ mission to redefine cancer treatment by advancing promising new biologics for individuals living with cancer,” said Yemi Onakunle, Selexis vice president, licensing and business development. “The Selexis team has a notable track record of success in helping our partners overcome protein-expression challenges and advance products rapidly and safely through the clinic to the market where they can be made available to patients in need.”